Rigel Pharmaceuticals’ Tavalisse (fostamatinib disodium hexahydrate) Receives FDA Approval for Chronic Immune Thrombocytopenia (ITP) in Adults

Rigel Pharmaceuticals’ Tavalisse (fostamatinib disodium hexahydrate) Receives FDA Approval for Chronic Immune Thrombocytopenia (ITP) in Adults

Shots:

  • The approval is based on three FIT studies results assessing Tavalisse (100/150mg, bid) vs Placebo in 150 patients with chronic ITP in ratio 2:1
  • The FIT studies result: FIT-1 (NCT02076399) stable platelets response (SPR) (18% vs 0%); FIT-2 (NCT02076412) SPR (16% vs 4%); FIT-3 (23%)
  • Tavalisse (fostamatinib disodium hexahydrate, PO) is a spleen tyrosine kinase (SYK) inhibitor and has received OD designation in Jan,2018

Click here to read full press release/ article | Ref: Rigel | Image: Glassdoor